Genome-wide approaches for cancer gene discovery

Trends in Biotechnology

Volumn 29, Issue 11, 2011, Pages 558-568

  Lizardi, Paul M ^a,b   Forloni, Matteo ^a   Wajapeyee, Narendra ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENES; CANCER GENOME; CANCER RESEARCH; CANCER THERAPY; CHROMATIN ORGANIZATION; FUNCTIONAL GENOMICS; HUMAN CANCER; IN-VIVO; RNA INTERFERENCE;

GENE THERAPY; RNA; TECHNOLOGY;

DISEASES;

CANCER GENETICS; CHROMATIN; DNA LIBRARY; GENE SEQUENCE; GENETIC IDENTIFICATION; GENOME ANALYSIS; GENOMICS; HIGH THROUGHPUT SCREENING; HIGH THROUGHPUT SEQUENCING; HUMAN; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TUMOR GENE;

ANIMALS; DATABASES, GENETIC; GENE EXPRESSION PROFILING; GENES, NEOPLASM; GENOME; GENOMICS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NEOPLASMS; RNA INTERFERENCE;

EID: 80054687429     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2011.06.003     Document Type: Review

References (77)

1. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
2. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
3. Ting A.H., et al. The cancer epigenome - components and functional correlates. Genes Dev. 2006, 20:3215-3231.
4. Takahashi T., et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989, 246:491-494.
5. Hollstein M., et al. p53 mutations in human cancers. Science 1991, 253:49-53.
6. Li J., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
7. Metzker M.L. Sequencing technologies-the next generation. Nat. Rev. Genet. 2010, 11:31-46.
8. Ley T.J., et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008, 456:66-72.
9. Mardis E.R., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 2009, 361:1058-1066.
10. Pleasance E.D., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196.
11. Taylor B.S., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
12. Lee W., et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010, 465:473-477.
13. Jones S., et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010, 330:228-231.
14. The Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
15. Verhaak R.G., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
16. Chiang D.Y., et al. High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat. Methods 2009, 6:99-103.
17. Chin L., et al. Making sense of cancer genomic data. Genes Dev. 2011, 25:534-555.
18. Mamanova L., et al. Target-enrichment strategies for next-generation sequencing. Nat. Methods 2010, 7:111-118.
19. Turner E.H., et al. Massively parallel exon capture and library-free resequencing across 16 genomes. Nat. Methods 2009, 6:315-316.
20. Hodges E., et al. Genome-wide in situ exon capture for selective resequencing. Nat. Genet. 2007, 39:1522-1527.
21. Jones S., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
22. Harbour J.W., et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010, 330:1410-1413.
23. Fire A., et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
24. Elbashir S.M., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
25. Hammond S.M., et al. Post-transcriptional gene silencing by double-stranded RNA. Nat. Rev. Genet. 2001, 2:110-119.
26. Chang K., et al. Lessons from Nature: microRNA-based shRNA libraries. Nat. Methods 2006, 3:707-714.
27. Paddison P.J., et al. A resource for large-scale RNA-interference-based screens in mammals. Nature 2004, 428:427-431.
28. Berns K., et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004, 428:431-437.
29. Silva J.M., et al. Second-generation shRNA libraries covering the mouse and human genomes. Nat. Genet. 2005, 37:1281-1288.
30. Bassik M.C., et al. Rapid creation and quantitative monitoring of high coverage shRNA libraries. Nat. Methods 2009, 6:443-445.
31. Silva J.M., et al. Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 2008, 319:617-620.
32. Schlabach M.R., et al. Cancer proliferation gene discovery through functional genomics. Science 2008, 319:620-624.
33. Gazin C., et al. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 2007, 449:1073-1077.
34. Gobeil S., et al. A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene. Genes Dev. 2008, 22:2932-2940.
35. Wajapeyee N., et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008, 132:363-374.
36. Palakurthy R.K., et al. Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNMT3B expression. Mol. Cell 2009, 36:219-230.
37. Sheng Z., et al. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat. Med. 2010, 16:671-677.
38. Zender L., et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008, 135:852-864.
39. Luo J., et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137:835-848.
40. Scholl C., et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137:821-834.
41. Hartwell L.H., et al. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997, 278:1064-1068.
42. Kaelin W.G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 2005, 5:689-698.
43. Luo J., et al. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
44. Boehm J.S., et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007, 129:1065-1079.
45. Maston G.A., et al. Transcriptional regulatory elements in the human genome. Annu. Rev. Genomics Hum. Genet. 2006, 7:29-59.
46. Schibler U., Sierra F. Alternative promoters in developmental gene expression. Annu. Rev. Genet. 1987, 21:237-257.
47. Ayoubi T.A., Van De Ven W.J. Regulation of gene expression by alternative promoters. FASEB J. 1996, 10:453-460.
48. Kimura K., et al. Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes. Genome Res. 2006, 16:55-65.
49. Baek D., et al. Characterization and predictive discovery of evolutionarily conserved mammalian alternative promoters. Genome Res. 2007, 17:145-155.
50. Davuluri R.V., et al. The functional consequences of alternative promoter use in mammalian genomes. Trends Genet. 2008, 24:167-177.
51. Liu S. Increasing alternative promoter repertories is positively associated with differential expression and disease susceptibility. PLoS ONE 2010, 5:e9482.
52. Lamprecht B., et al. Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat. Med. 2010, 16:571-579.
53. Singer G.A., et al. Genome-wide analysis of alternative promoters of human genes using a custom promoter tiling array. BMC Genomics 2008, 9:349.
54. Sun H., et al. Genome-wide mapping of RNA Pol-II promoter usage in mouse tissues by ChIP-seq. Nucleic Acids Res. 2010, 10.1093/nar/gkq775.
55. Barrera L.O., et al. Genome-wide mapping and analysis of active promoters in mouse embryonic stem cells and adult organs. Genome Res. 2008, 18:46-59.
56. Sandelin A., et al. Mammalian RNA polymerase II core promoters: insights from genome-wide studies. Nat. Rev. Genet. 2007, 8:424-436.
57. Carninci P., et al. Genome-wide analysis of mammalian promoter architecture and evolution. Nat. Genet. 2006, 38:626-635.
58. David C.J., Manley J.L. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 2010, 24:2343-2364.
59. Christofk H.R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
60. Christofk H.R., et al. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008, 452:181-186.
61. Mazurek S., et al. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 2005, 15:300-308.
62. Dombrauckas J.D., et al. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 2005, 44:9417-9429.
63. Richard H., et al. Prediction of alternative isoforms from exon expression levels in RNA-Seq experiments. Nucleic Acids Res. 2010, 38:e112.
64. Sultan M., et al. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 2008, 321:956-960.
65. Gupta S., et al. Genome wide identification and classification of alternative splicing based on EST data. Bioinformatics 2004, 20:2579-2585.
66. Pomerantz M.M., et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat. Genet. 2009, 41:882-884.
67. Vu T.H., et al. Loss of IGF2 imprinting is associated with abrogation of long-range intrachromosomal interactions in human cancer cells. Hum. Mol. Genet. 2010, 19:901-919.
68. Dekker J., et al. Capturing chromosome conformation. Science 2002, 295:1306-1311.
69. Lieberman-Aiden E., et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science 2009, 326:289-293.
70. Fullwood M.J., et al. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 2009, 462:58-64.
71. Balwierz P.J., et al. Methods for analyzing deep sequencing expression data: constructing the human and mouse promoterome with deepCAGE data. Genome Biol. 2009, 10:R79.
72. Kodzius R., et al. CAGE: cap analysis of gene expression. Nat. Methods 2006, 3:211-222.
73. Shiraki T., et al. Cap analysis gene expression for high-throughput analysis of transcriptional starting point and identification of promoter usage. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15776-15781.
74. Mattick J.S., et al. A global view of genomic information - moving beyond the gene and the master regulator. Trends Genet. 2010, 26:21-28.
75. Greenberg E.R., et al. Social and economic factors in the choice of lung cancer treatment. A population-based study in two rural states. N. Engl. J. Med. 1988, 318:612-617.
76. Xie Y., Minna J.D. Predicting the future for people with lung cancer. Nat. Med. 2008, 14:812-813.
77. Meyerson M., et al. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 2010, 11:685-696.